Abstract
Purpose
While gram negative (GN) periprosthetic joint infections (PJI) have previously been described as difficult to treat pathogens with high rates of reinfection, limited investigations have addressed midterm outcomes and risk of infection persistence by the same pathogen. This study analyzed (1) baseline demographics, treatment strategy, and midterm outcomes of GN PJIs, as well as (2) differences in reinfection and relapse rates compared to gram positive (GP) PJIs.
Methods
We identified 29 patients that were revised for 30 GN PJIs of total hip arthroplasties (THAs) between 2010 and 2020 using a university-based hip registry. Mean age was 77 years, 63% were females (19), and mean BMI was 27 kg/m2. Major causative pathogens included Escherichia coli (12), Klebsiella pneumoniae (5), Pseudomonas aeruginosa (5), and Enterobacter cloacae complex (5). Mean follow-up was 3.5 years. Study outcomes included (1) Kaplan–Meier survivorship analyses of all 30 GN PJIs, and (2) comparison of 18 two-stage exchanges for GN PJIs and 104 two-stage exchanges for GP PJIs, performed during the time from 2013 to 2017.
Results
(1) The 5-year survivorship free of recurrent PJI was 69%, and there were 7 recurrent PJIs at a mean of 2 years. There were 2 further suprafascial wound infections, resulting in a 61% survivorship free of any infection at 5-years. At a mean of 2 years, there were 7 patients with reinfection by the same GN pathogen (6 PJIs, one wound infection) as at index revision (23%). (2) Following two-stage exchange, the 5-year survivorship free of recurrent PJI (GN: 74%; GP: 91%; p = 0.072), any infection (GN: 61%; GP: 91%; p = 0.001), and reinfection by the same pathogen was significantly lower among GN PJIs (GN: 73%; GP: 98%; p < 0.001).
Conclusions
Patients revised for GN PJIs are at increased risk of reinfection as opposed to GP infections. Affected patients must be counseled on the exceptionally high risk of infection persistence with one in four developing relapses.
Level of evidence
Therapeutic Level III.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Outcomes of periprosthetic joint infections (PJIs) depend on a number of factors, including age, secondary diseases, previous revisions, soft tissue conditions, and treatment strategy [1, 2]. In addition to patient dependent and surgical risk factors, the involved pathogen is known to impact reinfection rates and long-term chances of cure [3]. Among Candida and rifampin resistant gram positive (GP) bacteria, PJIs caused by gram negatives (GN) have historically been associated with poor outcome [4,5,6].
Although GN bacteria are considered an atypical cause of PJI, they still represent an estimated 5 to 15% of all cases [1, 7]. Moreover, their prevalence is even further increased if affecting total hip arthroplasties (THAs) compared to total knee arthroplasties (Tande et al. Mayo Clinic PJI database) [1]. Despite increasing antibiotic multi resistance among GNs, an overall increase in numbers, and affecting nearly one in 10 prosthetic hip infections, only a handful of studies have addressed GN as causative agent for PJI [8, 9]. Moreover, did the limited studies on GN PJIs focus on a specific type of surgery only [10, 11], were primarily short-term reports [7, 12], or did not analyze reinfection characteristics and risk of infection persistence by the same pathogen in many cases [7, 12].
As such, this single university-based investigation analyzed GN PJIs in THAs at midterm outcome. We aimed to characterize baseline demographics, infection characteristics, and surgical strategies. Moreover, did this study determine the risk of infection persistence by the same GN pathogen, and analyzed differences between GP and GN PJIs with respect to reinfection and infection persistence rates.
Patients and methods
Study design
After obtaining institutional review board approval, we identified 29 patients that were revised for 30 GN prosthetic hip infections between 2010 and 2020. Mean age was 77 years (range, 56 to 89), mean BMI was 27 kg/m2 (range, 18 to 41 kg/m2), and 63% were females (19). Mean American Society of Anaesthesiologists (ASA) [13] score was 3 (range, 1 to 3). Five patients had diabetes mellitus, 3 rheumatoid arthritis, and 4 chronic obstructive pulmonary disease and hypothyroidism each. Mean follow-up was 3.5 years (range, 1 month to 7 years).
Pathogens
All 30 PJIs were confirmed infections according to the 2021 European Bone and Joint Infection Society (EBJIS) criteria [14]. GN pathogens included Escherichia coli (12), Klebsiella pneumoniae (5), Pseudomonas aeruginosa (5), and Enterobacter cloacae complex (5), Proteus mirabilis (2), Morganella morganii (2), Acinetobacter baumannii (2), Finegoldia magna (2), and Corynebacterium tuberculostearicum (1). Both patients affected by Finegoldia magna were simultaneously affected by Escherichia coli and Enterobacter cloacae complex, respectively. Seventeen of the 30 GN PJIs had a coexisting GP pathogen at time of revision (57%), including coagulase negative Staphylococci (CNS; 10), Staphylococcus aureus (4), Enterococcus faecalis (3), and one case of a mixed polymicrobial infection (Propionibacterium acnes, Enterococcus faecalis, Staphylococcus aureus, CNS) (Table 1). As such, 12 GN PJIs were monomicrobial (40%). Pathogens, for which no biofilm-active antibiotics were available were considered difficult-to-treat (DDT) pathogens [15]. In this series, those included rifampin-resistant Staphylococci (1), fluoroquinolone-resistant GN bacteria (6), and Enterococci (2). High-virulence pathogens were defined according Zimmerli et al. [16] and included Staphylococcus aureus, Streptococci and Enterococci. In our cohort, high-virulence bacteria were involved in 7 cases.
Infections
Infection type (I in 6, II in 4, and III in 20 patients), systemic host grade (A in 5, B in 17, C in 8 cases), and local risk factors (1 in 6, 2 in 16, 3 in 8 joints) were recorded based on the McPherson classification [17]. Among the 30 PJIs, there was one synchronous and one metachronous infection of other prosthetic joints. In total, 5 patients had an additional joint prosthesis (THAs or TKAs) at time of GN PJI. The only synchronous PJI in this cohort affected a patient with simultaneous infections of both of his THAs. There was one case of a metachronous infection of a contralateral THA with subsequent two-stage exchange one year prior to the GN PJI in this cohort. Twenty-six joints were revised prior to the current intervention (mean 3, range 1 to 8), including 21 for PJI (mean 2, range 1 to 5). Mean C-reactive-Protein (CRP) was 83 mg/l (range, 2 to 348 mg/l). Seven patients had a fistula at initial presentation (23%), 5 additional patients an abscess (17%). Fifteen THAs were cemented (50%), including 7 hybrid cementations (23%). Signs of loosening were noted in 15 acetabular and femoral components each (50%). Ten patients had loosening of both components prior to revision (33%).
Surgical procedures
For all patients with suspected PJI, our diagnostic algorithm included preoperative aspirations, intraoperative collection of at least five tissue samples of different localization, as well as sonication of explanted material and intraoperative aspirations, if possible [18]. In our center, an acute PJI with adequate bone and soft tissue quality, a fixed prosthesis, and no involvement of DDT pathogens was addressed by debridement and preservation of the prosthesis with surgical exchange of the mobile components (DAIR). In the case of chronic PJI with a symptom onset of more than 4 weeks, complete prosthesis removal was performed. Thereby a two-stage exchange was used in the presence of DTT pathogens, fistulae or multiple prior revisions, as well as in culture negative infections. We considered long-term antibiotic suppression in the setting of an unsatisfactory outcome, when eradication of the infection was not possible [19]. Two-stage exchange was performed in 18, one-stage exchange and debridement, antibiotics and implant retention with exchange of mobile parts (DAIR) in 5 cases each, whereas permanent resection arthroplasty was necessary in 2 patients (Table 1). In case of two-stage exchanges, mean time between resection arthroplasty and reimplantation was 10 weeks (range, 4 to 25 weeks), and interim debridement performed in 9 cases (50%). In 4 of the 9 cases, the same GN pathogen was identified compared to resection arthroplasty (3-times Escherichia coli, one-time Proteus mirabilis). Mean time required for implant removal and reimplantation were 139 min (range, 29 to 265 min) and 177 min (range, 84 to 299 min), respectively.
Statistical analysis
Study endpoints included survivorship free of PJI, any infection, and reinfection by the same pathogen (relapse). The 2021 EBJIS criteria were used to define recurrent PJI [14], whereas any infection was considered any PJI and any additional supra fascial wound infection with identification of a pathogen (as opposed to simple wound healing delay). Secondary endpoints included a comparison of survivorship between two-stage exchanges performed for GN as opposed to GP PJIs. Survivorship analysis was based on Kaplan Meier curves [20]. Differences in survivorship were calculated using a log-rank test, differences in continuous variables with a t- and Whitney-U-man test, and differences between categorial variables via a fisher-exact test. SAS version 9.4 (SAS Institute, Inc., Cary, North Carolina) was used for calculations.
Results
Outcome
The 5-year survivorship free of death was 76% (95% CI 56 to 96%; 10 patients at risk). Five patients died at a mean of 2 years (range, 6 days to 5 years). One patient died by perioperative non PJI related complications. Likewise, none of the other 4 patients died by PJI related complications. The 5-year survivorship free of any recurrent PJI was 69% (95% CI 50 to 89%; 14 patients at risk), and there were 7 recurrent PJIs at a mean of 2 years (range, 16 days to 4 years). There were 2 further suprafascial wound infection with identification of pathogens at 2 months (Finegoldia magna) and 5 months (Bacillus cereus, Propionibacterium acnes), resulting in a 5-year survivorship free of any infection of 61% (95% CI 40 to 81%; 12 patients at risk). At a mean of 2 years, there were 7 patients (6 PJIs, one wound infection) with reinfection by the same GN pathogen as at index revision (23%). Cases of reinfection by the same pathogen involved Escherichia coli (3), Pseudomonas aeruginosa (2), Enterobacter cloacae (1) and Proteus mirabilis (1). In addition to the above-mentioned infection related revisions, there was one liner exchange for dislocation at one month. There were 2 further non-operative complications, and both were closed reductions for dislocations at one and 3 months (Table 1). Mean preoperative Harris Hip Score [21] was 29 (range, 12 to 48) and increased to 60 (range, 19 to 70) at last follow-up.
GN versus GP PJI
A total of 18 patients underwent two-stage exchange for GN PJI in this cohort. Two-stage exchanges was used as a comparison group, representing the most commonly used treatment type in our clinic. During the same time period, between 2013 and 2017, there were 104 patients that were revised with a two-stage exchange for GP PJI, 8 of which had a recurrent PJI. Culture negative PJIs were excluded for comparison. Except a statistically significantly higher age among patients treated for GN PJIs, both groups did not differ in baseline demographics (Table 2). Following two-stage exchange, the 5-year survivorship free of recurrent PJI (GN: 74%, GP: 91%; p = 0.072) (Fig. 1), any infection (GN: 61%, GP: 91%; p = 0.001), and reinfection by the same pathogen were all significantly lower among GN PJIs (GN: 73%, GP: 98%; p < 0.001).
Kaplan–Meier survival curves of 18 GN and 104 GP two-stage THA exchange revisions. Curves with censored data (vertical spikes) are shown for the two cohorts (red graph: GN PJI, blue graph: GP PJIs). Five-year survivorship free of recurrent PJI was 74% (95% CI 58.9 to 81.3) and 91% (95% CI 89.5 to 94.9), respectively
Discussion
While the number of PJIs will increase significantly over the next decades [22, 23], limited remains known on GN PJIs. As such, we analyzed 29 patients affected by 30 GN PJIs at a mean of 3.5 years follow-up. We found nearly one in 4 patients to experience infection persistence by the same pathogen at a mean of 2 years. In addition, we identified the rate of infection persistence to be significantly higher compared to GP cases at midterm follow-up.
Knowledge on baseline demographics of patients affected by periprosthetic hip infection is important, as certain pathogens are attributable to specific risk populations [24]. We found GN PJIs to primarily affect elderly, multimorbid, and overweight patients. These factors are also reflected by a poor local and systemic McPherson grade. In fact, two in three joints were revised for PJI in the past. This also confirms findings of Akkaya et al. that identified a significantly increased rate of DTT pathogens, including GN infections, in 66 patients with failed one-stage exchange of the knee [25]. Importantly, however, a comparison with GP PJIs revealed no statistically significant difference, except a higher age among GN cases. Of note, a higher age among GN PJIs falls in line with one previous report [7], although other studies could not confirm this finding [5, 26]. While prelim findings indicate similar baseline demographics between GN and GP PJIs, larger population samples will be needed to determine potential epidemiological differences in the future [5, 7, 26].
The leading GN pathogen in this cohort was Escherichia coli (40%), reflecting most previous studies on GN PJIs [5, 9]. Importantly, this investigation found a high percentage of polymicrobial and mixed GP-GN infections. In fact, only 40% of cases were monomicrobial. This rate is substantially lower than previously reported and might represent the fact that this investigation had a 70% proportion of patients that were revised for PJI in the past, as opposed to previous studies focusing on first time PJIs only [7]. We believe the inclusion of mixed GN-GP infections to be important, as it more accurately reflects the majority of patients encountered in clinic.
Outcomes of GN PJIs are known to be poor, with survivorship rates free of recurrent PJI to be reported as low as 27% at 2 years for implant retention attempts [7]. Importantly, the majority of previous studies did report of short-term outcomes only [5, 7, 9]. In contrast, this investigation analyzed midterm outcomes and found a 69% survivorship free of PJI recurrence at 5 years. This falls in line with the 5-year outcomes of 2 studies on DAIR for GN PJIs, although treatment failure was defined broader in both investigations [12, 27].
Similar to one previous investigation, we found the rate of reinfection to be significantly higher among GN as opposed to GP PJIs [7]. Importantly, we performed a detailed follow-up on the risk of infection persistence, and found nearly one in 4 patients to develop infection relapse by the same GN pathogen at a mean of 2 years. A similarly high rate of relapse was also reported by Martínez-Pastor et al. [10] with 8 of 35 patients experiencing relapse with the same GN pathogen at a median follow-up of 463 days. Uniquely, this investigation found relapse rates to be significantly increased compared to the GP group. This finding is important, as it demonstrates a unique feature of GN PJIs: patients are at risk of infection relapse rather than new infection by a different pathogen.
We acknowledge limitations to this study. First of all, did we present a single center cohort study with a subsequent low patient number in the light of an overall rare condition. Moreover, were treatment approaches and patient characteristics heterogenous, reducing comparability with existing studies. Finally, did this study not report GN PJIs in isolation, but rather included a high proportion of mixed and polymicrobial infections, as encountered in the daily clinical routine. This finding possibly impacts prognosis [28], although the polymicrobial infection rate were comparable to GP pathogens in the course of a two-stage exchange sub-analysis.
In conclusion, this investigation found GN PJIs to affect high-risk cohorts with the majority of patients being revised for PJI in the past. GN rarely occurred in isolation, but present with a high rate of polymicrobial infections (60%). Patients should be counseled on the increased risk of reinfection compared to GP PJIs, as well as a high chance of infection persistence by the same pathogen (23%). Based on our findings, we recommend prolonged suppression therapy of at least three months if involving GN pathogens. Future studies should focus on long-term outcomes, as well as multi center-based cohorts to increase the number of patients in a rare but difficult to treat condition.
References
Tande AJ, Patel R (2014) Prosthetic joint infection. Clin Microbiol Rev 27(2):302–345. https://doi.org/10.1128/CMR.00111-13
Davis JS, Metcalf S, Clark B et al (2022) Predictors of treatment success after periprosthetic joint infection: 24-month follow up from a multicenter prospective observational cohort study of 653 patients. Open Forum Infect Dis 9(3):ofac048. https://doi.org/10.1093/ofid/ofac048
Wimmer MD, Hischebeth GTR, Randau TM et al (2022) Difficult-to-treat pathogens significantly reduce infection resolution in periprosthetic joint infections. Diagn Microbiol Infect Dis 98(2):115114. https://doi.org/10.1016/j.diagmicrobio.2020.115114
Karczewski D, Ren Y, Andronic O et al (2022) Candida periprosthetic joint infections - risk factors and outcome between albicans and non-albicans strains. Int Orthop 46(3):449–456. https://doi.org/10.1007/s00264-021-05214-y
Zmistowski B, Fedorka CJ, Sheehan E, Deirmengian G, Austin MS, Parvizi J (2011) Prosthetic joint infection caused by gram-negative organisms. J Arthroplasty 26(6 Suppl):104–108. https://doi.org/10.1016/j.arth.2011.03.044
Darwich A, Dally FJ, Abu Olba K et al (2021) Superinfection with difficult-to-treat pathogens significantly reduces the outcome of periprosthetic joint infections. Antibiotics (Basel) 10(10):1145. https://doi.org/10.3390/antibiotics10101145
Hsieh PH, Lee MS, Hsu KY, Chang YH, Shih HN, Ueng SW (2009) Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 49(7):1036–1043. https://doi.org/10.1086/605593
Benito N, Franco M, Ribera A et al (2016) Time trends in the aetiology of prosthetic joint infections: a multicentre cohort study. Clin Microbiol Infect 22(8):732.e1-732.e7328. https://doi.org/10.1016/j.cmi.2016.05.004
Fantoni M, Borrè S, Rostagno R et al (2019) Epidemiological and clinical features of prosthetic joint infections caused by gram-negative bacteria. Eur Rev Med Pharmacol Sci 23(2 Suppl):187–194. https://doi.org/10.26355/eurrev_201904_17490
Martínez-Pastor JC, Muñoz-Mahamud E, Vilchez F et al (2009) Outcome of acute prosthetic joint infections due to gram-negative bacilli treated with open debridement and retention of the prosthesis. Antimicrob Agents Chemother 53(11):4772–4777. https://doi.org/10.1128/AAC.00188-09
Premkumar A, Kolin DA, Farley KX et al (2021) Projected economic burden of periprosthetic joint infection of the hip and knee in the United States. J Arthroplast 36(5):1484-1489.e3. https://doi.org/10.1016/j.arth.2020.12.005
Rodríguez-Pardo D, Pigrau C, Lora-Tamayo J et al (2014) Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect 20(11):O911–O919. https://doi.org/10.1111/1469-0691.12649
Daabiss M (2011) American society of anaesthesiologists physical status classification. Indian J Anaesth 55(2):111–115. https://doi.org/10.4103/0019-5049.79879
McNally M, Sousa R, Wouthuyzen-Bakker M et al (2021) The EBJIS definition of periprosthetic joint infection. Bone Joint J 103-B(1):18–25. https://doi.org/10.1302/0301-620X.103B1.BJJ-2020-1381.R1
Akgün D, Perka C, Trampuz A, Renz N (2018) Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to biofilm-active antibiotics: results from a prospective cohort study. Arch Orthop Trauma Surg 138(5):635–642. https://doi.org/10.1007/s00402-018-2886-0
Zimmerli W, Trampuz A, Ochsner PE (2004) Prosthetic-joint infections. N Engl J Med 351(16):1645–1654. https://doi.org/10.1056/NEJMra040181
McPherson EJ, Tontz W Jr, Patzakis M et al (1999) Outcome of infected total knee utilizing a staging system for prosthetic joint infection. Am J Orthop (Belle Mead NJ) 28(3):161–165
Izakovicova P, Borens O, Trampuz A (2019) Periprostetic joint infection: current concepts and outlook. Effort Open Rev 4(7):482–494. https://doi.org/10.1302/2058-5241.4.180092
Karczewski D, Winkler T, Renz N, Trampuz A, Lieb E, Perka C, Müller M (2019) A standardized interdisciplinary algorithm for the treatment of prosthetic joint infections. Bone Joint J 101-B(2):132–139. https://doi.org/10.1302/0301-620X.101B2.BJJ-2018-1056.R1
Bland JM, Altman DG (1998) Survival probabilities (the Kaplan-Meier method). BMJ 317(7172):1572 (Epub 1998/12/04)
Harris WH (1969) Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am 51(4):737–755
Chang CH, Lee SH, Lin YC, Wang YC, Chang CJ, Hsieh PH (2020) Increased periprosthetic hip and knee infection projected from 2014 to 2035 in Taiwan. J Infect Public Health 13(11):1768–1773. https://doi.org/10.1016/j.jiph.2020.04.014
O’Toole P, Maltenfort MG, Chen AF, Parvizi J (2016) Projected increase in periprosthetic joint infections secondary to rise in diabetes and obesity. J Arthroplast 31(1):7–10. https://doi.org/10.1016/j.arth.2015.07.034
Tai DBG, Patel R, Abdel MP, Berbari EF, Tande AJ (2022) Microbiology of hip and knee periprosthetic joint infections: a database study. Clin Microbiol Infect 28(2):255–259. https://doi.org/10.1016/j.cmi.2021.06.006
Akkaya M, Vles G, Bakhtiari IG et al (2022) What is the rate of reinfection with different and difficult-to-treat bacteria after failed one-stage septic knee exchange? Int Orthop 46(4):687–695. https://doi.org/10.1007/s00264-021-05291-z
Uçkay I, Bernard L (2010) Gram-negative versus gram-positive prosthetic joint infections. Clin Infect Dis 50(5):795. https://doi.org/10.1086/650540
Jaén N, Martínez-Pastor JC, Muñoz-Mahamud E et al (2012) Long-term outcome of acute prosthetic joint infections due to gram-negative bacilli treated with retention of prosthesis. Rev Esp Quimioter 25(3):194–198
Marculescu CE, Cantey JR (2008) Polymicrobial prosthetic joint infections: risk factors and outcome. Clin Orthop Relat Res 466(6):1397–1404. https://doi.org/10.1007/s11999-008-0230-7
Acknowledgements
Not applicable.
Funding
Open Access funding enabled and organized by Projekt DEAL. There is no funding source.
Author information
Authors and Affiliations
Contributions
Primary data analysis (JS, DK, CH, DA), literature analysis (DK, JS, CH, DA, MG, SH), writing (DK, JS, MG, SH), statistics (MG, DK), internal review (DK, JS, CH, DA, MG, SH).
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
Approved by institutional review board.
Informed consent
Not applicable.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Investigation performed at the Charité University Medicine Berlin, Germany.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Karczewski, D., Scholz, J., Hipfl, C. et al. Gram negative periprosthetic hip infection: nearly 25% same pathogen infection persistence at a mean of 2 years. Arch Orthop Trauma Surg (2023). https://doi.org/10.1007/s00402-023-05104-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00402-023-05104-5